Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry
Section snippets
Experimental procedures
All experiments were performed using lumbar DRGs obtained from male Wistar rats (150–200 g) except for experiments performed on DRGs taken from CB1-knockout mice (CB1−/−) and wild type mice. CB1−/− mice and wild type mice were obtained from colonies maintained by Dr. D. Baker at the Institute of Neurology, London; the CB1−/− mice were derived from knockout-mice originally generated by Ledent et al. (1999). All experiments conformed to British Home Office regulations for laboratory animals. The
Distribution of cb1 mrna
Both of the two in situ hybridisation probes used in this study produced identical results. For quantification a combination of the two probes was used to give a stronger signal. Addition of a 20-fold excess of unlabeled oligonucleotides to the hybridisation reaction mix effectively competed all specific binding of radiolabeled probe. Positive cells were indicated by clusters of silver grains, with specific labelling above background of CB1 mRNA seen in 22.7±1.5% of the total cell profiles.
Discussion
In this study we have determined the expression profile of the CB1 receptor in the DRG of naive rats using both in situ hybridisation and immunohistochemical techniques. In our results there appear to be some differences in the amount of co-expression of CB1 with other markers using these two techniques detecting CB1 mRNA and protein respectively (compare Table 1, Table 2). However, the general patterns and extent of co-expression are quite similar. Although we cannot rule out the possibility
Acknowledgements
The authors would like to thank Dr. D. Julius and Dr. Q. Yan for provision of antibodies to G.J.M. and Dr. D. Baker for provision of CB1−/− mice. G.J.M. would like to thank Dr. J. V. Priestley for support as well as encouragement throughout this project. This work is supported by grants from the Medical Research Council, the Association of Anaesthetists and the Wellcome Trust (grant 057058 awarded to M.R.E. and grant 058542 awarded to Dr. J. V. Priestley). Part of this study was presented at
References (50)
- et al.
Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons
Neuroscience
(2000) - et al.
Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive primary sensory neurones
Neuroscience
(2002) - et al.
GDNF family neurotrophic factor signalingfour masters, one servant?
Mol Cell Neurosci
(1999) - et al.
Arvanil-induced inhibition of spasticity and persistent painevidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors
Eur J Pharmacol
(2002) - et al.
Cannabinoid CB1 receptor expression in rat spinal cord
Mol Cell Neurol
(2000) - et al.
The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain
Pain
(2001) - et al.
The analgesic effects of R(+)-Win 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
Neurosci Lett
(1997) - et al.
Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root gangliaa double label study in situ hybridization study
Neuroscience
(1999) - et al.
Cannabinoid receptors undergo axonal flow in sensory nerves
Neuroscience
(1999) - et al.
Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord
Brain Res
(1999)
Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal chord following neonatal capsaicin treatment
Neurosci Lett
Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2
Neurosci Lett
The anti-hyperalgesic actions of the cannabinoid anadamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
Pain
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats
Neuroscience
Expression of capsaicin receptor (VR1) by myelinated primary afferent neurons in rats
Neurosci Lett
Expression and coexpression of Trk receptors in subpopulations of adult primary sensory neurons projecting to identified peripheral targets
Neuron
Antihyperalgesic effects of spinal cannabinoids
Eur J Pharmacol
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
Pain
Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord
Neuroscience
An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing
J Biol Chem
The cloned capsaicin receptor integrates multiple pain-producing stimuli
Neuron
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Neuroscience
mGlu5 receptors and nociceptive functionII
mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology
A distinct subgroup of small DRG cells express GDNF receptor components and GDNF is protective for these neurons after nerve injury
J Neurosci
Potent analgesic effects of GDNF in neuropathic pain states
Science
Cited by (142)
Cannabinoid receptor 1 positive allosteric modulator (GAT229) attenuates cisplatin-induced neuropathic pain in mice
2023, Saudi Pharmaceutical JournalCitation Excerpt :Available data suggest that GAT229 treatment normalizes the expression of NGF and BDNF, which might attenuate CIS neurotoxicity and CIPN pain. Exposure to chemotherapeutic agents such as CIS and oxaliplatin activates NF-kB signaling pathways, increasing pro-inflammatory cytokine expression, including TNF-α, IL-1β, and IL-6 in the DRGs neurons (Fumagalli et al., 2021; Burakgazi et al., 2011; Wang et al., 2012). Induction of the expression of pro-inflammatory cytokines is involved in the development of CIPN-induced mechanical hyperalgesia and IENFs degenerations (Bennett et al., 2011; Boyette-Davis et al., 2011).
Evaluation of protective effects of non-selective cannabinoid receptor agonist WIN 55,212-2 against the nitroglycerine-induced acute and chronic animal models of migraine: A mechanistic study
2019, Life SciencesCitation Excerpt :Moreover, spinally administration of WIN 55,212-2 diminishes thermal hyperalgesia in diabetic rats but this effect is not more effective rather than the systematic administration [40]. Additionally, it has been showed that a systemic administration of cannabinoid ligand WIN55,212-2 is effective in decreasing the mechanical allodynia in different animal models of pain [41,42]. Interestingly, in the chronic model, we observed that both middle and high doses of WIN 55,212-2 (1 and 3 mg/kg, respectively) also produce obvious analgesic effects against chronic administration of NTG at both spinal and supraspinal levels.
Cannabinoids-induced peripheral analgesia depends on activation of BK channels
2019, Brain ResearchThe Involvement of the Endocannabinoid System in the Peripheral Antinociceptive Action of Ketamine
2018, Journal of PainCitation Excerpt :Our results show that AM251 was able to antagonize, in a dose-dependent manner, the peripheral antinociception induced by ketamine. Indeed, CB1 receptors are densely expressed in the dorsal root ganglia and in the peripheral terminals of primary afferent neurons,2,10,35 which anatomically supports the finding that antinociception induced by the local administration of ketamine occurs partly through these receptors. However, treatment with the CB2 receptor antagonist (AM630) was unable to reverse the peripheral antinociceptive effect of ketamine at the maximum dose previously reported to reverse the effect of a CB2 CBR agonist.57
Expression of Cannabinoid Receptors in the Trigeminal Ganglion of the Horse
2023, International Journal of Molecular Sciences